PRG Immune Blend Research Capsules (BPC-157, KPV & Larazotide)

PRG Gastro-Immune Blend

BPC-157 500mcg, KPV 500mcg, Larazotided 250mcg

While the original PRG Gastro blend delivers balanced support for general gut integrity, the PRG Gastro-Immune Blend provides concentrated peptide levels to deliver more comprehensive intervention at the molecular interface between mucosal repair, tight junction stability, and cytokine regulation. This advanced profile targets the interconnected cycle of barrier breach, sustained inflammation, and impaired healing that characterizes more complex gastrointestinal conditions.

The PRG Gastro-Immune Blend combines BPC-157, KPV, and Larazotide to deliver advanced support for gut health and immune balance. These peptides work together to promote deeper tissue repair in the digestive tract. BPC-157 helps strengthen natural healing processes within the stomach and intestinal lining. KPV assists in controlling inflammation at the cellular level inside the gut. Larazotide helps reinforce the protective connections between intestinal cells. This higher-potency combination addresses multiple layers of gastrointestinal challenges simultaneously. It targets the gut-immune interface for more complete restoration of normal function. Many people face persistent digestive issues that involve both barrier weakness and ongoing inflammation. The blend aims to provide intensified assistance in re-establishing gut equilibrium. Overall, the PRG Gastro-Immune.

Blend serves as an upgraded option for comprehensive gastrointestinal and immune wellness. At the molecular level, the PRG Gastro-Immune Blend amplifies the established actions of its components to achieve more pronounced effects on gastrointestinal homeostasis. Elevated concentrations enable stronger upregulation of angiogenic and cytoprotective pathways, more effective intracellular suppression of pro-inflammatory transcription factors, and tighter regulation of junctional complexes, resulting in synergistic restoration of mucosal architecture. This formulation is positioned for scenarios where standard peptide support may benefit from escalation, offering a targeted approach to breaking cycles of permeability-driven immune activation and delayed healing.

Molecular Mechanisms of Action at the Molecular Level

BPC-157 functions as a stable pentadecapeptide originally identified in gastric juice, where it exerts cytoprotective effects on gastrointestinal epithelial and endothelial cells. At the molecular level, it upregulates vascular endothelial growth factor expression and activates the nitric oxide pathway through endothelial nitric oxide synthase, leading to enhanced angiogenesis and improved blood supply to damaged mucosal areas. This process supports fibroblast proliferation, collagen organization, and expression of early growth response-1 gene, which collectively accelerate extracellular matrix remodeling and tissue regeneration in the stomach and intestinal lining. BPC-157 also modulates oxidative stress responses by reducing lipid peroxidation and preserving mitochondrial function in stressed cells, thereby limiting apoptosis during injury.

KPV, the tripeptide Lys-Pro-Val derived from alpha-melanocyte stimulating hormone, is taken up directly by intestinal epithelial cells via the PepT1 proton-coupled oligopeptide transporter. Once intracellular, it inhibits the activation of nuclear factor kappa B and downstream mitogen-activated protein kinase cascades, which in turn suppresses the transcription and release of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 from both epithelial and resident immune cells. This targeted dampening of inflammatory signaling occurs without broad immunosuppression, preserving normal immune surveillance in the gut mucosa while promoting resolution of acute inflammatory episodes.

Larazotide, an octapeptide, acts as a specific regulator of paracellular permeability by interfering with zonulin-mediated signaling. It prevents the phosphorylation of myosin light chain and the subsequent reorganization of the actin cytoskeleton and zonula occludens-1 protein complexes at tight junctions. As a result, the integrity of the epithelial barrier is maintained, limiting the passage of luminal antigens, bacteria, and toxins into the submucosa. This mechanism operates locally within the intestinal epithelium and does not require systemic absorption for its primary effect.

Potential Clinical Applications in Gastrointestinal Disorders

The combined molecular actions position the PRG Gastro blend as a multi-targeted support for conditions characterized by mucosal injury, chronic inflammation, and barrier dysfunction. In ulcerative colitis and Crohn’s disease, the blend could aid in mucosal healing by promoting angiogenesis and collagen deposition while simultaneously reducing cytokine-driven damage and preventing further antigen translocation across a compromised barrier. For non-steroidal anti-inflammatory drug-induced gastropathy and peptic ulcers, BPC-157’s cytoprotective and angiogenic properties may accelerate re-epithelialization of erosions, with KPV limiting local inflammatory amplification and Larazotide preserving junctional integrity to reduce secondary bacterial involvement.

In celiac disease and gluten-related disorders, Larazotide’s tight junction stabilization could blunt the gliadin-triggered increase in permeability, thereby decreasing immune activation in the lamina propria; this effect would be complemented by KPV’s cytokine suppression and BPC-157’s regenerative support to the damaged villous architecture. For irritable bowel syndrome subtypes with documented intestinal hyperpermeability, the blend may restore barrier competence and calm low-grade mucosal inflammation, potentially improving symptoms of bloating, pain, and altered motility. Post-infectious or radiation-induced enteritis represents another setting where rapid resolution of epithelial damage and inflammation could shorten recovery time and reduce fibrotic sequelae. Ischemic bowel injury or anastomotic healing after surgical resection could also benefit from enhanced microvascularization and controlled inflammation, minimizing complications such as leaks or strictures.

The formulation’s ability to act locally within the gastrointestinal lumen and mucosa makes it suitable for adjunctive use in complex, refractory cases where conventional therapies address only one aspect of pathology. Because the peptides operate through distinct but interconnected pathways—regeneration, inflammation resolution, and barrier reinforcement—the blend offers a rational strategy for breaking the vicious cycle of leak-inflammation-further damage that underlies many chronic gastrointestinal disorders.

Summary of Animal and Human Trials

Extensive preclinical work in rodent models has established robust efficacy for each component. In rat and mouse models of acetic acid-, ethanol-, or indomethacin-induced gastric ulcers, BPC-157 consistently accelerated mucosal restitution, reduced lesion size, and improved histological scores through enhanced angiogenesis and nitric oxide modulation. DSS- and TNBS-induced colitis models demonstrated that BPC-157 preserved colonic architecture, lowered myeloperoxidase activity, and promoted fistula closure when administered in drinking water or locally. Similar protective effects were observed in ischemia-reperfusion injury and surgical anastomosis studies, with faster healing and reduced adhesions.

KPV showed marked anti-inflammatory activity in the same DSS and TNBS colitis models, where oral administration via drinking water significantly decreased body weight loss, disease activity index, histological inflammation scores, and colonic levels of TNF-α and IL-6. In vitro studies on Caco-2 and HT-29 monolayers confirmed intracellular uptake via PepT1 and direct inhibition of NF-κB-driven cytokine production. Larazotide prevented zonulin-induced permeability increases in gluten-challenged animal models and in cytokine-exposed intestinal segments, maintaining transepithelial electrical resistance and limiting bacterial translocation.

Human data, while more limited for some components, support translational potential. BPC-157 has advanced to phase II evaluation in patients with ulcerative colitis, where it demonstrated safety and signals of endoscopic improvement and symptom relief. Pilot observations in fistulizing Crohn’s disease further highlighted its healing capacity. KPV, or its closely related analog K(D)PT, has been assessed in early-phase studies for ulcerative colitis, showing encouraging rates of clinical remission and mucosal healing with a favorable safety profile. Larazotide has progressed through multiple phase II and III trials in celiac disease patients, including gluten-challenge protocols; results indicated reductions in gastrointestinal symptoms, decreased anti-tissue transglutaminase antibody titers in some cohorts, and overall good tolerability, although larger studies encountered statistical challenges on primary endpoints related to permeability markers. Across these investigations, the peptides were generally well tolerated with minimal systemic side effects attributable to their local mechanisms of action.

Why the PRG Gastro Blend Might Work: Synergistic Arguments

The PRG Gastro blend leverages complementary mechanisms that collectively interrupt the interconnected pathophysiology of gastrointestinal injury. Larazotide first reinforces the epithelial barrier by stabilizing tight junctions, thereby reducing the influx of luminal antigens and microbial products that perpetuate inflammation. This upstream protection creates a more favorable environment for KPV to exert its intracellular anti-inflammatory effects, allowing NF-κB inhibition to resolve rather than merely suppress cytokine storms within an already leaky mucosa. With inflammation controlled and antigen exposure minimized, BPC-157 can more efficiently drive angiogenesis, fibroblast activation, and epithelial regeneration without competing against ongoing damage signals.

This sequential and synergistic targeting—barrier preservation, inflammation resolution, and active tissue repair—addresses the full triad of events that sustain chronic gut disorders. In isolation, a single peptide might improve one parameter but leave others unchecked; for example, healing agents alone may be less effective if persistent permeability re-exposes tissue to triggers, while anti-inflammatory agents may not restore structural integrity. The blend’s multi-pronged approach mirrors the body’s own layered defense and repair systems, potentially leading to faster, more durable mucosal recovery and reduced risk of relapse compared with monotherapy. Preclinical models of complex colitis support the rationale that simultaneous modulation of permeability, cytokine networks, and angiogenic pathways yields additive or supra-additive histological and functional improvements. For patients with refractory or multifactorial gastrointestinal conditions, this comprehensive strategy offers a biologically plausible advantage by aligning peptide actions with the sequential stages of injury and resolution observed at the cellular and tissue levels.

Molecular Mechanisms of Action at the Molecular Level

BPC-157 functions as a stable pentadecapeptide originally identified in gastric juice, where it exerts cytoprotective effects on gastrointestinal epithelial and endothelial cells. At the molecular level, it upregulates vascular endothelial growth factor expression and activates the nitric oxide pathway through endothelial nitric oxide synthase, leading to enhanced angiogenesis and improved blood supply to damaged mucosal areas. This process supports fibroblast proliferation, collagen organization, and expression of early growth response-1 gene, which collectively accelerate extracellular matrix remodeling and tissue regeneration in the stomach and intestinal lining. BPC-157 also modulates oxidative stress responses by reducing lipid peroxidation and preserving mitochondrial function in stressed cells, thereby limiting apoptosis during injury.

KPV, the tripeptide Lys-Pro-Val derived from alpha-melanocyte stimulating hormone, is taken up directly by intestinal epithelial cells via the PepT1 proton-coupled oligopeptide transporter. Once intracellular, it inhibits the activation of nuclear factor kappa B and downstream mitogen-activated protein kinase cascades, which in turn suppresses the transcription and release of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 from both epithelial and resident immune cells. This targeted dampening of inflammatory signaling occurs without broad immunosuppression, preserving normal immune surveillance in the gut mucosa while promoting resolution of acute inflammatory episodes.

Larazotide, an octapeptide, acts as a specific regulator of paracellular permeability by interfering with zonulin-mediated signaling. It prevents the phosphorylation of myosin light chain and the subsequent reorganization of the actin cytoskeleton and zonula occludens-1 protein complexes at tight junctions. As a result, the integrity of the epithelial barrier is maintained, limiting the passage of luminal antigens, bacteria, and toxins into the submucosa. This mechanism operates locally within the intestinal epithelium and does not require systemic absorption for its primary effect.

Potential Clinical Applications in Gastrointestinal Disorders

The combined molecular actions position the PRG Gastro blend as a multi-targeted support for conditions characterized by mucosal injury, chronic inflammation, and barrier dysfunction. In ulcerative colitis and Crohn’s disease, the blend could aid in mucosal healing by promoting angiogenesis and collagen deposition while simultaneously reducing cytokine-driven damage and preventing further antigen translocation across a compromised barrier. For non-steroidal anti-inflammatory drug-induced gastropathy and peptic ulcers, BPC-157’s cytoprotective and angiogenic properties may accelerate re-epithelialization of erosions, with KPV limiting local inflammatory amplification and Larazotide preserving junctional integrity to reduce secondary bacterial involvement.

In celiac disease and gluten-related disorders, Larazotide’s tight junction stabilization could blunt the gliadin-triggered increase in permeability, thereby decreasing immune activation in the lamina propria; this effect would be complemented by KPV’s cytokine suppression and BPC-157’s regenerative support to the damaged villous architecture. For irritable bowel syndrome subtypes with documented intestinal hyperpermeability, the blend may restore barrier competence and calm low-grade mucosal inflammation, potentially improving symptoms of bloating, pain, and altered motility. Post-infectious or radiation-induced enteritis represents another setting where rapid resolution of epithelial damage and inflammation could shorten recovery time and reduce fibrotic sequelae. Ischemic bowel injury or anastomotic healing after surgical resection could also benefit from enhanced microvascularization and controlled inflammation, minimizing complications such as leaks or strictures.

The formulation’s ability to act locally within the gastrointestinal lumen and mucosa makes it suitable for adjunctive use in complex, refractory cases where conventional therapies address only one aspect of pathology. Because the peptides operate through distinct but interconnected pathways—regeneration, inflammation resolution, and barrier reinforcement—the blend offers a rational strategy for breaking the vicious cycle of leak-inflammation-further damage that underlies many chronic gastrointestinal disorders.

Summary of Animal and Human Trials

Extensive preclinical work in rodent models has established robust efficacy for each component. In rat and mouse models of acetic acid-, ethanol-, or indomethacin-induced gastric ulcers, BPC-157 consistently accelerated mucosal restitution, reduced lesion size, and improved histological scores through enhanced angiogenesis and nitric oxide modulation. DSS- and TNBS-induced colitis models demonstrated that BPC-157 preserved colonic architecture, lowered myeloperoxidase activity, and promoted fistula closure when administered in drinking water or locally. Similar protective effects were observed in ischemia-reperfusion injury and surgical anastomosis studies, with faster healing and reduced adhesions.

KPV showed marked anti-inflammatory activity in the same DSS and TNBS colitis models, where oral administration via drinking water significantly decreased body weight loss, disease activity index, histological inflammation scores, and colonic levels of TNF-α and IL-6. In vitro studies on Caco-2 and HT-29 monolayers confirmed intracellular uptake via PepT1 and direct inhibition of NF-κB-driven cytokine production. Larazotide prevented zonulin-induced permeability increases in gluten-challenged animal models and in cytokine-exposed intestinal segments, maintaining transepithelial electrical resistance and limiting bacterial translocation.

Human data, while more limited for some components, support translational potential. BPC-157 has advanced to phase II evaluation in patients with ulcerative colitis, where it demonstrated safety and signals of endoscopic improvement and symptom relief. Pilot observations in fistulizing Crohn’s disease further highlighted its healing capacity. KPV, or its closely related analog K(D)PT, has been assessed in early-phase studies for ulcerative colitis, showing encouraging rates of clinical remission and mucosal healing with a favorable safety profile. Larazotide has progressed through multiple phase II and III trials in celiac disease patients, including gluten-challenge protocols; results indicated reductions in gastrointestinal symptoms, decreased anti-tissue transglutaminase antibody titers in some cohorts, and overall good tolerability, although larger studies encountered statistical challenges on primary endpoints related to permeability markers. Across these investigations, the peptides were generally well tolerated with minimal systemic side effects attributable to their local mechanisms of action.

The PRG Gastro blend leverages complementary mechanisms that collectively interrupt the interconnected pathophysiology of gastrointestinal injury. Larazotide first reinforces the epithelial barrier by stabilizing tight junctions, thereby reducing the influx of luminal antigens and microbial products that perpetuate inflammation. This upstream protection creates a more favorable environment for KPV to exert its intracellular anti-inflammatory effects, allowing NF-κB inhibition to resolve rather than merely suppress cytokine storms within an already leaky mucosa. With inflammation controlled and antigen exposure minimized, BPC-157 can more efficiently drive angiogenesis, fibroblast activation, and epithelial regeneration without competing against ongoing damage signals.

This sequential and synergistic targeting—barrier preservation, inflammation resolution, and active tissue repair—addresses the full triad of events that sustain chronic gut disorders. In isolation, a single peptide might improve one parameter but leave others unchecked; for example, healing agents alone may be less effective if persistent permeability re-exposes tissue to triggers, while anti-inflammatory agents may not restore structural integrity. The blend’s multi-pronged approach mirrors the body’s own layered defense and repair systems, potentially leading to faster, more durable mucosal recovery and reduced risk of relapse compared with monotherapy. Preclinical models of complex colitis support the rationale that simultaneous modulation of permeability, cytokine networks, and angiogenic pathways yields additive or supra-additive histological and functional improvements. For patients with refractory or multifactorial gastrointestinal conditions, this comprehensive strategy offers a biologically plausible advantage by aligning peptide actions with the sequential stages of injury and resolution observed at the cellular and tissue levels.